Click or
tap here
to read our
newsletter

It takes broad experience to develop and produce biologic medicines.

Creating biologic medicines requires a high degree of scientific knowledge. Just as critically important is the process by which these medicines are produced. It’s a highly technical, multistep process, requiring broad and deep experience in science, technology, and meticulous quality control.2

Boehringer Ingelheim has that experience.

Boehringer Ingelheim has been manufacturing biologics for over 35 years.3,4

Trusted

Fifteen of the top 20 global pharmaceutical companies have relied on us to make their biologic medicines.5

Experienced

We have extensive experience manufacturing interferons, monoclonal antibodies, and other targeted medicines.6

Invested

We continuously invest in the highly technical manufacturing process and have expanded our global facilities to meet the increasing demand for biologics and biosimilars.7

Innovation and experience:

Boehringer Ingelheim, 1885-present

Click or tap each box to expand

  • 1885

    Boehringer Ingelheim founded with 28 employees.9

    1955

    Boehringer Ingelheim establishes Animal Health division.10

    1970s

    Boehringer Ingelheim expands to the US.10

  • 1912

    Boehringer Ingelheim launches its first drug, Laudanon®.11

    1963

    Groundbreaking research into chicken interferon.7

    1983

    Boehringer Ingelheim registers its first biologic, interferon alpha.7

    2002

    Boehringer Ingelheim launches the first once-daily inhaled COPD therapy.12,13

  • 1946

    Biberach R&D site opened.10

    2011

    Boehringer Ingelheim acquires a biopharma plant in Fremont, CA.14

    2017

    Boehringer Ingelheim opens the first multinational biopharmaceutical manufacturing facility in China.15

  • 1995

    Boehringer Ingelheim begins manufacturing biologics for leading pharma companies.7

    2017

    Fifteen of the world’s top 20 pharmaceutical companies have relied on us to make their biologic medicines.5

  • 2016

    Boehringer Ingelheim and Sarah Cannon Research Institute launch collaborative cancer research.16

    2017

    50,000 employees worldwide.8

    2017

    opnMe.com molecule-sharing initiative launched.17

History

Family-owned and research-driven since 1885.8

1885

Boehringer Ingelheim founded with 28 employees.9

1955

Boehringer Ingelheim establishes Animal Health division.10

1970s

Boehringer Ingelheim expands to the US.10

Innovation

In 1983, we registered our first biologic, interferon alpha.7

1912

Boehringer Ingelheim launches its first drug, Laudanon®.11

1963

Groundbreaking research into chicken interferon.7

1983

Boehringer Ingelheim registers its first biologic, interferon alpha.7

2002

Boehringer Ingelheim launches the first once-daily inhaled COPD therapy.12,13

Experience

We’ve been making biologic medicines as a contract manufacturer since 1995.7

1946

Biberach R&D site opened.10

2011

Boehringer Ingelheim acquires a biopharma plant in Fremont, CA.14

2017

Boehringer Ingelheim opens the first multinational biopharmaceutical manufacturing facility in China.15

Trust

Fifteen of the world’s top 20 pharmaceutical companies have relied on us to make their biologics.5

1995

Boehringer Ingelheim begins manufacturing biologics for leading pharma companies.7

2017

Fifteen of the world’s top 20 pharmaceutical companies have relied on us to make their biologic medicines.5

Leadership

We’ve manufactured 29 biologics to date; three of them are among the most-prescribed medicines in the world today.5

2016

Boehringer Ingelheim and Sarah Cannon Research Institute launch collaborative cancer research.16

2017

50,000 employees worldwide.8

2017

opnMe.com molecule-sharing initiative launched.17

Experience means supply chain integrity.18

Boehringer Ingelheim is highly committed to delivering safe and efficacious medicines to our patients. We are dedicated to ensuring:

  • Patient safety and end-to-end supply chain security
  • Current industry standards for product verification measures based on mass serialization and tamper-resistant packaging
  • Thorough and vigorous investigation of incidents that lead to violations of supply chain integrity and aggressive prosecution

For over 35 years, we've delivered.

Experience means consistent quality.

We pride ourselves on maintaining state-of-the-art assays and other techniques to determine the potency, safety, and purity of every drug we make.2 Our production plants operate under CGMP (Current Good Manufacturing Practice regulations enforced by FDA).19

Experience means investing in infrastructure.

We’re committed to global leadership in biologics and biosimilars. One example: We invested $217 million to expand our Fremont, California, facilities. Boehringer Ingelheim has 4 biologic manufacturing facilities that can perform the entire production technology chain, from cell culturing to sterile packaging, under one roof3:

  • Fremont, California, USA
  • Biberach, Germany
  • Vienna, Austria
  • Shanghai, China

Few can match our 35 years of biologic manufacturing experience.3

From high-expression systems to formulation development, fill and finish, or patient-convenient application systems—all potential elements of a successful outsourcing project can be found within the Boehringer Ingelheim BioXcellence™ one-stop-shop seamless services.20

See our story unfold in 3 minutes.

For more information about our contract manufacturing capabilities, go to:

www.bioxcellence.com

Few can match our dedication to consistently and reliably delivering the medicines patients need.

References:
  1. 1. Brainy quote website. https://www.brainyquote.com/quotes/albert_einstein_148778. Accessed June 8, 2018.
  2. 2. Boehringer Ingelheim website. Manufacturing at a glance. https://www.bioxcellence.com/about_us/about_biotechnology/manufacturing_process_glance.html. Accessed June 27, 2018.
  3. 3. Boehringer Ingelheim BioXcellence. Producing value: global contract manufacturing excellence. November 2015.
  4. 4. Boehringer Ingelheim website. Contract Manufacturing. https://www.bioxcellence.com/contract_manufacturing.html/. Accessed May 15, 2018.
  5. 5. Data on file. Ridgefield, CT: Boehringer Ingelheim Biopharmaceuticals, Inc.
  6. 6. Boehringer Ingelheim website. Boehringer Ingelheim extends "one stop shop” service with new fill and finish capabilities. https://www.bioxcellence.com/press_archive/press/2011/20_june_2011_onestopshop.html. Accessed June 5, 2018.
  7. 7. Boehringer Ingelheim website. Boehringer Ingelheim’s history in biotechnology. https://www.bioxcellence.com/about_us/about_biotechnology/history.html. Accessed June 12, 2018.
  8. 8. Boehringer Ingelheim website. A successful and independent corporation. Boehringer Ingelheim. https://www.boehringer-ingelheim.com/who-we-are/our-company. Accessed June 29, 2018.
  9. 9. Boehringer Ingelheim website. A successful and independent corporation. History. https://www.boehringer-ingelheim.com/who-we-are/history. Accessed May 15, 2018.
  10. 10. Boehringer Ingelheim website. 1948-1988: Going global. https://www.boehringer-ingelheim.com/history/history-milestone/1948-1988. Accessed June 27, 2018.
  11. 11. Boehringer Ingelheim website. 1885-1948: Innovative beginnings. https://www.boehringer-ingelheim.com/history/history-milestone/1885-1948. Accessed July 13, 2018.
  12. 12. Boehringer Ingelheim website. 1988-2015: Value through innovation. https://www.boehringer-ingelheim.com/history/history-milestone/1988-2015. Accessed June 29, 2018.
  13. 13. Evaluategroup.com website. Boehringer Ingelheim receives European approval of SPIRIVA® for the treatment of COPD. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=24763. Accessed July 19, 2018.
  14. 14. Boehringer Ingelheim website. Press release. Boehringer Ingelheim to purchase Amgen’s Fremont (USA) facility. https://www.bioxcellence.com/press_archive/press/2011/18_january_2011_amgen.html. Published January 18, 2011. Accessed July 13, 2018.
  15. 15. Boehringer Ingelheim website. Press release. Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China. https://www.boehringer-ingelheim.com/press-release/Biopharma-Manufacturing-Facility-in-China-inaugurated. Published May 16, 2017. Accessed June 12, 2018.
  16. 16. Boehringer Ingelheim website. Press release. Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies. https://www.boehringer-ingelheim.com/press-release/sarah-cannon-collaboration. Published September 29, 2016. Accessed February 6, 2018.
  17. 17. Boehringer Ingelheim website. Press release. Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential. https://www.boehringer-ingelheim.com/New-platform-opnMe-for-access-to-molecules-for-research. Published November 20, 2017. Accessed July 13, 2018.
  18. 18. Boehringer Ingelheim website. Position Statement: Patient Safety & Supply Chain Security. https://www.boehringer-ingelheim.us/sites/us/files/files/bi-position-statement_patientsafetysupplychainsecurity.pdf. Accessed September 6, 2018.
  19. 19. Boehringer Ingelheim website. cGMP manufacturing. https://www.bioxcellence.com/contract_manufacturing/cgmp_manufacturing.html. Accessed June 27, 2018.
  20. 20. Boehringer Ingelheim website. Seamless manufacturing. https://www.bioxcellence.com/about_us/one_stop_shop.html. Accessed June 27, 2018.